Skip to content
Open access

Complement drives PNH red cell hemolysis independently of inflammasome activation

Jul 2026 · medRxiv · 0 citations
Medicine

TL;DR

It is shown that the destruction of PNH erythrocytes is a consequence of the MAC-calcium-calpain axis, rather than an inflammatory programmed cell death event, which means therapeutic strategies aimed at targeting the inflammasome or caspase signaling will likely offer no clinical benefit for PNH patients.

Abstract

Paroxysmal Nocturnal Hemoglobinuria (PNH) is characterized by hemolysis due to the loss of GPI-anchored complement regulators. While terminal complement inhibitors improve survival, the precise intracellular mechanisms driving the destruction of PNH erythrocytes remain controversial. A recently proposed model suggests PNH cells undergo an inflammatory programmed cell death ("spectosis") driven by an NLRP3-Caspase-8 signaling cascade. Here, we use a whole packed cell lysis approach to map the cytoskeletal degradation of primary erythrocytes across a 22-patient PNH cohort. Our data show that membrane attack complex (MAC) pore formation drives targeted {beta}-spectrin fragmentation, which correlates with rapid intracellular potassium (K+) efflux. Notably, when probing these primary patient samples, we detected a complete absence of the NLRP3 protein and found no functional evidence of Caspase-8 activation during MAC pore formation. Furthermore, caspase inhibition did not alter cytoskeletal degradation or K+ efflux. Instead, our data demonstrate that MAC-induced membrane perforation permits a rapid influx of calcium, which activates calpain, the dominant calcium-dependent protease in erythrocytes. Rather than an inflammatory cascade, this calcium-dependent calpain activity executes the degradation of {beta}-spectrin. These findings challenge current models of PNH hemolysis. We show that the destruction of PNH erythrocytes is a consequence of the MAC-calcium-calpain axis, rather than an inflammatory programmed cell death event. Consequently, therapeutic strategies aimed at targeting the inflammasome or caspase signaling will likely offer no clinical benefit for PNH patients.

Read PDF

Similar papers

Review Open access Aug 2026

Interleukin-6 in hemolytic anemias: from inflammatory pathways to therapeutic targeting

Hemolytic anemias comprise inherited and acquired disorders characterized by premature red blood cell destruction. Increasing evidence indicates that many forms of hemolysis are accompanied by sustained inflammatory and immune activation. Red blood cell breakdown releases damage-associated molecular patterns, including...

Manjun Zhao, Xin Yu · 0 citations
Review Open access Sep 2026

Interplay between mitophagy, ferroptosis, and pyroptosis in acute pancreatitis: Regulatory mechanisms and therapeutic implications.

BACKGROUND With a very high death rate, acute pancreatitis (AP) is a frequent acute abdominal illness of the digestive system. It is challenging for the conventional notion of "trypsin self digestion" to adequately explain the molecular underpinnings of local inflammation that spreads across the body and the heterogene...

Jia-Lei Li, Shan-Qing Gao, Li Gao et al. · 0 citations
Open access Sep 2026

Platelet-erythrocyte complex production is exacerbated by histones and protected by small polyanion histone neutralizing compounds.

Platelet-erythrocyte (PE) complexes, composed of single erythrocytes bound to platelets, are a physiological component of the bloodstream and contribute to erythrocyte turnover. Conditions in which PE complex production is increased or their clearance from the circulation is impeded are associated with hypercoagulable...

Vichari Sirimanne, Jiwon Lee, Melanie Rug et al. · 0 citations
Open access Aug 2026

Expression of Active Apurinic Apyrimidinic Endodeoxyribonuclease 1 in Human Platelets

The first evidence for the expression levels and subcellular localization of apurinic/apyrimidinic endodeoxyribonuclease 1 (APE1), evaluated alongside cytosolic and mitochondrial markers, in resting human PLTs isolated from a cohort of healthy donors is provided.

Isabella Parolini, Alessia Bellina, G. Carpi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.